{"id":52749,"date":"2023-01-10T14:02:24","date_gmt":"2023-01-10T13:02:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/"},"modified":"2023-01-10T14:02:24","modified_gmt":"2023-01-10T13:02:24","slug":"atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/","title":{"rendered":"ATCC Announces Participation with Aret\u00e9 on IARPA Contract to Develop New Methods for Identifying Low-Dose Radiation Exposure"},"content":{"rendered":"
\n

\nATCC to provide biological standards to support research efforts of the Targeted Evaluation of Ionizing Radiation Exposure (TEI-REX) program.<\/i>\n<\/p>\n

MANASSAS, Va.–(BUSINESS WIRE)–ATCC<\/a>, the world\u2019s premier biological materials management and standards organization, today announced that it would be supporting Aret\u00e9<\/a>, one of the four winning teams awarded a contract from the Intelligence Advanced Research Projects Activity (IARPA<\/a>), the research and development arm of the Office of the Director of National Intelligence (ODNI), to develop novel methods for Targeted Evaluation of Ionizing Radiation Exposure (TEI-REX).\n<\/p>\n

<\/a><\/p>\n

\nAccording to IARPA<\/a>, it is pursuing new technologies to identify low-dose radiation exposure, determine the exposure timeline and pinpoint environmental factors related to the place of exposure. The TEI-REX program research goals are to protect better the health and safety of the intelligence community and military and government personnel overseas while supporting nuclear counterproliferation efforts. IARPA aims to build a fundamentally new understanding of low-dose radiation\u2019s physical impacts on humans and organisms through advances in artificial intelligence, machine learning, biomarker discovery, and analytical biology.\n<\/p>\n

\n\u201cAs a global biological resource center, ATCC can provide high-quality biological standards for the TEI-REX program to aid scientists in their research efforts,\u201d said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC. \u201cThis is the first time that ATCC, as a subcontractor with Aret\u00e9, has supported IARPA and its mission to push the boundaries of science to develop solutions that empower the intelligence community to do its work better and more efficiently for national security.\u201d\n<\/p>\n

\nCurrent radiation biodosimetry technologies used to assess the effects of ionizing radiation on people may require invasive methods, such as a blood draw or tissue sample, as well as multiple collections because of the short time limit for accurate readings. Results are often variable and transient, especially at low doses. These limitations make it difficult to assess exposure on a mass scale.\n<\/p>\n

\nNew assays using biological markers may result in more robust, accurate, and quicker ways to detect the effects of ionizing radiation on humans. Through the TEI-REX program, IARPA hopes to engineer new non-invasive technologies using samples obtained from hair, skin, sweat, and saliva, which will be easier to collect, store, ship, and analyze for months.\n<\/p>\n

\n\u201cATCC is pleased to be on the team with Aret\u00e9 in developing a novel, non-invasive assay for detecting low-level ionizing radiation,\u201d said Dr. Joseph Leonelli, Senior Vice President, ATCC Federal Solutions. \u201cOur participation in this IARPA contract demonstrates ATCC\u2019s commitment to protecting US military, intelligence, and other government personnel deployed globally, especially in environments where nuclear technology could be used.\u201d\n<\/p>\n

\n\u201cAt Aret\u00e9, our goal is to provide superior solutions to national and global challenges,\u201d said Karyn Apfeldorf, Ph.D., Data Analytics Group Lead at Aret\u00e9. \u201cWith ATCC\u2019s expertise, assay development resources, and critical biological reagents to support the team\u2019s work on this contract, I know we can help the TEI-REX program find new technologies to provide greatly enhanced characterization and quantification of low-dose radiation exposure better.\u201d\n<\/p>\n

\nAbout ATCC<\/b>\n<\/p>\n

\nATCC is a premier global biological materials and information resource and standards organization and the leading developer and supplier of authenticated cell lines, microorganisms and associated data for academia, industry and government. With a history of scientific contributions spanning nearly a century, ATCC offers an unmatched combination of being the world\u2019s largest and most diverse collection of biological reference materials and data, and is a mission-driven, trusted partner that supports and encourages scientific collaboration. ATCC products, services, partnerships, and people provide the global scientific community with credible, advanced model systems to support complex research and innovations in basic science, drug discovery, translational medicine, and public health. ATCC is a 501(c)3 nonprofit organization with headquarters in Manassas, Virginia, and a research and technology center of excellence in Gaithersburg, Maryland. To learn more, visit atcc.org<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKim Testa, Senior Director, Corporate Communications & Public Affairs, ATCC, pr@atcc.org<\/a>.\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ATCC to provide biological standards to support research efforts of the Targeted Evaluation of Ionizing Radiation Exposure (TEI-REX) program. MANASSAS, Va.–(BUSINESS WIRE)–ATCC, the world\u2019s premier biological materials management and standards organization, today announced that it would be supporting Aret\u00e9, one of the four winning teams awarded a contract from the Intelligence Advanced Research Projects Activity … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52749","6":"format-standard","7":"category-industry"},"yoast_head":"\nATCC Announces Participation with Aret\u00e9 on IARPA Contract to Develop New Methods for Identifying Low-Dose Radiation Exposure - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ATCC Announces Participation with Aret\u00e9 on IARPA Contract to Develop New Methods for Identifying Low-Dose Radiation Exposure - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ATCC to provide biological standards to support research efforts of the Targeted Evaluation of Ionizing Radiation Exposure (TEI-REX) program. MANASSAS, Va.–(BUSINESS WIRE)–ATCC, the world\u2019s premier biological materials management and standards organization, today announced that it would be supporting Aret\u00e9, one of the four winning teams awarded a contract from the Intelligence Advanced Research Projects Activity ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-10T13:02:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230110005175\/en\/1283762\/21\/ATCC_logo600.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ATCC Announces Participation with Aret\u00e9 on IARPA Contract to Develop New Methods for Identifying Low-Dose Radiation Exposure\",\"datePublished\":\"2023-01-10T13:02:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\\\/\"},\"wordCount\":666,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005175\\\/en\\\/1283762\\\/21\\\/ATCC_logo600.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\\\/\",\"name\":\"ATCC Announces Participation with Aret\u00e9 on IARPA Contract to Develop New Methods for Identifying Low-Dose Radiation Exposure - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005175\\\/en\\\/1283762\\\/21\\\/ATCC_logo600.jpg\",\"datePublished\":\"2023-01-10T13:02:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005175\\\/en\\\/1283762\\\/21\\\/ATCC_logo600.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005175\\\/en\\\/1283762\\\/21\\\/ATCC_logo600.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ATCC Announces Participation with Aret\u00e9 on IARPA Contract to Develop New Methods for Identifying Low-Dose Radiation Exposure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ATCC Announces Participation with Aret\u00e9 on IARPA Contract to Develop New Methods for Identifying Low-Dose Radiation Exposure - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/","og_locale":"en_US","og_type":"article","og_title":"ATCC Announces Participation with Aret\u00e9 on IARPA Contract to Develop New Methods for Identifying Low-Dose Radiation Exposure - Pharma Trend","og_description":"ATCC to provide biological standards to support research efforts of the Targeted Evaluation of Ionizing Radiation Exposure (TEI-REX) program. MANASSAS, Va.–(BUSINESS WIRE)–ATCC, the world\u2019s premier biological materials management and standards organization, today announced that it would be supporting Aret\u00e9, one of the four winning teams awarded a contract from the Intelligence Advanced Research Projects Activity ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-10T13:02:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230110005175\/en\/1283762\/21\/ATCC_logo600.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ATCC Announces Participation with Aret\u00e9 on IARPA Contract to Develop New Methods for Identifying Low-Dose Radiation Exposure","datePublished":"2023-01-10T13:02:24+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/"},"wordCount":666,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230110005175\/en\/1283762\/21\/ATCC_logo600.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/","url":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/","name":"ATCC Announces Participation with Aret\u00e9 on IARPA Contract to Develop New Methods for Identifying Low-Dose Radiation Exposure - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230110005175\/en\/1283762\/21\/ATCC_logo600.jpg","datePublished":"2023-01-10T13:02:24+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230110005175\/en\/1283762\/21\/ATCC_logo600.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230110005175\/en\/1283762\/21\/ATCC_logo600.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/atcc-announces-participation-with-arete-on-iarpa-contract-to-develop-new-methods-for-identifying-low-dose-radiation-exposure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ATCC Announces Participation with Aret\u00e9 on IARPA Contract to Develop New Methods for Identifying Low-Dose Radiation Exposure"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52749"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52749\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}